ZURICH, July 9 Pharmaceutical group Novartis
NOVN.VX said on Monday it had received U.S. approval for
Exelon Patch, which delivers a treatment for Alzheimer's disease
through a skin patch instead of an oral capsule.
The medication was submitted for review in the European
Union in late 2006, Novartis said.
The Federal Food and Drug Administration (FDA) also approved
the use of Exelon Patch in treating patients with mild to
moderate Parkinson's disease dementia, Novartis said.
The Exelon Patch, which is applied to the back, chest or
upper arm, maintains steady drug levels in the bloodstream,
improving tolerability and allowing a higher proportion of
patients to receive therapeutic doses of medication, with
potential improvements in efficacy, Novartis said.
Alzheimer's disease is a progressive, degenerative disease
that alters the brain, causing impaired memory, thinking and
Approximately 18 million people worldwide have Alzheimer's
disease, Novartis said.
Parkinson's disease is a chronic and progressive neurological
condition that affects approximately 1.5 million people in the
United States. Two out of five people with Parkinson's disease
are estimated to have Parkinson's disease dementia.